Health service arm CIGNA Group CI and EVERNERTH recently introduced pharmacy benefits offering designed to improve access to weight loss drugs Wegovy and Zepbound. This innovative offering solves important market demand by providing cheap access to weight loss pharmaceuticals to both patients and health plan sponsors.
For patients, the monthly cofpe of the GLP-1 weight loss drug is limited to $ 200 or less and offers more cheaper options than the cash payment program. In addition, these cofilles will contribute to the patient’s annual deduction. This contract can cause up to $ 3,600 savings per year compared to purchasing drugs directly or through alternative consumer programs.
In addition, the patient will approach the FDA approval treatment combined with the safety protocol of the Express Scripts, designed to minimize the risk of harmful drug interactions. The preliminary approval process is also simplified and automated, allowing you to approach these drugs faster. The patient is supported by the addition of flexibility that can be selected from a wide range of local retail pharmacy networks, or by selecting home delivery through Evernort’s ENGUIDE Pharmacy to support GLP-1 drugs and strengthen treatment.
Employers and other health plan sponsors stand to get significant benefits from this new offering. One of the main advantages is that the total net cost per prescription of GLP-1 drugs is significantly reduced, resulting in meaningful cost savings. In addition, health planning sponsors can allow patients to access drugs that are most suitable for individual needs, and maintain both clinical safety and cost efficiency without sacrificing the quality of choice or treatment.
EVERNORTH’s motivation is to use the GLP-1 solution product line to improve meaningful cost savings and health results for existing customers. The new pharmacy offering is expected to upgrade the comprehensive GLP-1 solution product line. In addition to the recent additional additional additional solutions, the Solution Suites also includes more than 9 million lives and the Encirclerx, a cost-saving financial model that has saved $ 200 million in health planning since 2024, and features REACHRX, a personalized clinical support program designed to provide support for distributing GLP-1 prescription drugs.
The profitability of the new pharmacy benefits is likely to attract new customers by maintaining existing customers and choosing GLP-1 solutions. The increase in the use of the solution is expected to bring higher profits to the Evernorth sector. This will suits the parent company CIGNA. The device occupies a significant portion of CI revenue. In the first quarter of 2025, EVERNORTH contributed 82%to CIGNA’s total adjustment income.
